Hepavax-Gene is a recombinant hepatitis B vaccine. It is said to be one of the World Health Organization’s pre-qualified vaccines for immunization against hepatitis B virus.
According to the company, Hepavax-Gene possesses two decisive advantages; its production is based on Crucell’s hansenula polymorpha patented technology and it is 100% free of thiomersal.
Ronald Brus, CEO of Crucell, said: “The launch of Hepavax-Gene is a significant advancement in the expansion of Crucell’s business in the Chinese vaccine market. Hepavax-Gene will contribute significantly to the sustainability of our Chinese operations.”